As a result of these improvements, the therapeutic efficacy of both Doxil nanomedicine and ICI cocktail (anti-PD-1 and anti-CTLA-4) was significantly elevated, highlighting the potential of this combined approach to optimize treatment outcomes in a tumor setting. This evidence concerns the gene CTLA4 and neoplasm.